These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 20303574

  • 1. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ.
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 3. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 9. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [Abstract] [Full Text] [Related]

  • 10. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL.
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.
    Yee CH, Ng CF, Wong AY, Chan CK, Hou SM, Yip SK.
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):168-73. PubMed ID: 21585697
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [Abstract] [Full Text] [Related]

  • 15. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [Abstract] [Full Text] [Related]

  • 16. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R, Gesztesi Z, Rochford J.
    Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 18. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK, Weston R, Parr NJ.
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 20. Editorial comment.
    Tan WW.
    Urology; 2010 May; 75(5):1143. PubMed ID: 20451736
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.